+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anti-Thrombin III Testing Market by Product Type, Technology, Application, End User - Global Forecast 2025-2030- Product Image
Anti-Thrombin III Testing Market by Product Type, Technology, Application, End User - Global Forecast 2025-2030- Product Image
Sale

Anti-Thrombin III Testing Market by Product Type, Technology, Application, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 197 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6015079
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Anti-Thrombin III Testing Market grew from USD 91.43 million in 2023 to USD 99.84 million in 2024. It is expected to continue growing at a CAGR of 9.39%, reaching USD 171.37 million by 2030.

Anti-Thrombin III Testing is a crucial component in diagnosing and managing thrombotic disorders, where the focus is on evaluating levels of anti-thrombin, a key protein inhibiting blood clot formation. This diagnostic testing is vital in identifying congenital and acquired deficiencies, which are associated with increased risk of thromboembolism. The application scope extends across hospitals, diagnostic labs, and research institutes, where the tests support clinicians in devising treatment strategies for conditions such as liver disease, nephrotic syndrome, and disseminated intravascular coagulation. Growth in the anti-thrombin III testing market is driven by increasing prevalence of cardiovascular diseases, heightened awareness about thrombosis risks, and advancements in diagnostic technologies, such as automation in laboratory settings. An aging global population and elevated healthcare expenditure further bolster demand. However, high testing costs, limited accessibility in developing regions, and stringent regulatory environments present challenges. Opportunities lie in expanding into emerging markets with tailored, cost-effective solutions, and integrating AI and machine learning for enhanced prediction and personalization of treatment. Continued investment in research on novel biomarkers and development of non-invasive testing methods can spur innovation. Strategic partnerships with healthcare providers and emphasis on patient education could strengthen market positioning. Looking forward, businesses should capitalize on the increasing emphasis on preventive healthcare and personalized medicine. Focusing resources on improving the accuracy, speed, and accessibility of anti-thrombin III testing can yield substantial returns. The market is inherently competitive yet carries potential for substantial growth, particularly as global health priorities tilt towards early diagnosis and management of thrombotic conditions. Industry stakeholders are encouraged to navigate regulatory landscapes adeptly and foster collaborations that drive innovation and broaden the reach of advanced diagnostic solutions.

Understanding Market Dynamics in the Anti-Thrombin III Testing Market

The Anti-Thrombin III Testing Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Rising number of surgical procedures requiring anti-thrombin III monitoring for better perioperative care
    • Increase in geriatric population prone to thrombotic disorders necessitating regular anti-thrombin III testing
    • Expansion of healthcare infrastructure in emerging economies
  • Market Restraints
    • Limited availability of skilled professionals and specialized laboratories for anti-thrombin III testing
  • Market Opportunities
    • Expansion of anti-thrombin III testing services in specialized cardiovascular care facilities
    • Collaborations with biotechnology firms to innovate new anti-thrombin III testing methodologies
  • Market Challenges
    • Regulatory compliance and stringent guidelines

Exploring Porter’s Five Forces for the Anti-Thrombin III Testing Market

Porter’s Five Forces framework further strengthens the insights of the Anti-Thrombin III Testing Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Anti-Thrombin III Testing Market

External macro-environmental factors deeply influence the performance of the Anti-Thrombin III Testing Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Anti-Thrombin III Testing Market

The Anti-Thrombin III Testing Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Anti-Thrombin III Testing Market

The Anti-Thrombin III Testing Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Anti-Thrombin III Testing Market

The Anti-Thrombin III Testing Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anti-Thrombin III Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Becton, Dickinson and Company, Bio-Rad Laboratories, bioMérieux, Chrono-log Corporation, Danaher Corporation, DiaSorin, Grifols, Immucor, Instrumentation Laboratory, Merck KGaA, PerkinElmer, Quidel Corporation, Roche Diagnostics, Sekisui Diagnostics, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific, and Werfen.

Market Segmentation & Coverage

This research report categorizes the Anti-Thrombin III Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Product Type
    • Cardiac Test Kits
    • ELISA Test Kits
    • FIA Test Kits
  • Technology
    • Chromogenic Assay
    • Immunoassay
  • Application
    • Diagnostic Laboratories
      • Hospital Laboratories
      • Independent Diagnostics Laboratories
    • Point of Care Testing
    • Research and Academic Institutes
      • Clinical Research Units
      • Universities & Colleges
  • End User
    • Ambulatory Surgical Centers
    • Diagnostic Laboratories
    • Hospitals
    • Specialty Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising number of surgical procedures requiring anti-thrombin III monitoring for better perioperative care
5.1.1.2. Increase in geriatric population prone to thrombotic disorders necessitating regular anti-thrombin III testing
5.1.1.3. Expansion of healthcare infrastructure in emerging economies
5.1.2. Restraints
5.1.2.1. Limited availability of skilled professionals and specialized laboratories for anti-thrombin III testing
5.1.3. Opportunities
5.1.3.1. Expansion of anti-thrombin III testing services in specialized cardiovascular care facilities
5.1.3.2. Collaborations with biotechnology firms to innovate new anti-thrombin III testing methodologies
5.1.4. Challenges
5.1.4.1. Regulatory compliance and stringent guidelines
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Anti-Thrombin III Testing Market, by Product Type
6.1. Introduction
6.2. Cardiac Test Kits
6.3. ELISA Test Kits
6.4. FIA Test Kits
7. Anti-Thrombin III Testing Market, by Technology
7.1. Introduction
7.2. Chromogenic Assay
7.3. Immunoassay
8. Anti-Thrombin III Testing Market, by Application
8.1. Introduction
8.2. Diagnostic Laboratories
8.2.1. Hospital Laboratories
8.2.2. Independent Diagnostics Laboratories
8.3. Point of Care Testing
8.4. Research and Academic Institutes
8.4.1. Clinical Research Units
8.4.2. Universities & Colleges
9. Anti-Thrombin III Testing Market, by End User
9.1. Introduction
9.2. Ambulatory Surgical Centers
9.3. Diagnostic Laboratories
9.4. Hospitals
9.5. Specialty Clinics
10. Americas Anti-Thrombin III Testing Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Anti-Thrombin III Testing Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Anti-Thrombin III Testing Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. ANTI-THROMBIN III TESTING MARKET RESEARCH PROCESS
FIGURE 2. ANTI-THROMBIN III TESTING MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
FIGURE 9. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 13. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS ANTI-THROMBIN III TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS ANTI-THROMBIN III TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES ANTI-THROMBIN III TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES ANTI-THROMBIN III TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC ANTI-THROMBIN III TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC ANTI-THROMBIN III TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTI-THROMBIN III TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTI-THROMBIN III TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. ANTI-THROMBIN III TESTING MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. ANTI-THROMBIN III TESTING MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. ANTI-THROMBIN III TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. ANTI-THROMBIN III TESTING MARKET DYNAMICS
TABLE 7. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY CARDIAC TEST KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY ELISA TEST KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY FIA TEST KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY CHROMOGENIC ASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY INDEPENDENT DIAGNOSTICS LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY CLINICAL RESEARCH UNITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY UNIVERSITIES & COLLEGES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS ANTI-THROMBIN III TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 44. BRAZIL ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 45. BRAZIL ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 46. BRAZIL ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 47. BRAZIL ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. CANADA ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 49. CANADA ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 50. CANADA ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 51. CANADA ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 52. CANADA ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 53. CANADA ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 54. MEXICO ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 55. MEXICO ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 56. MEXICO ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 57. MEXICO ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 58. MEXICO ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 59. MEXICO ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES ANTI-THROMBIN III TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 67. ASIA-PACIFIC ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 68. ASIA-PACIFIC ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 69. ASIA-PACIFIC ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 70. ASIA-PACIFIC ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 71. ASIA-PACIFIC ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 72. ASIA-PACIFIC ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 73. ASIA-PACIFIC ANTI-THROMBIN III TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 74. AUSTRALIA ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 75. AUSTRALIA ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 76. AUSTRALIA ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 77. AUSTRALIA ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 78. AUSTRALIA ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 79. AUSTRALIA ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. CHINA ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 81. CHINA ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 82. CHINA ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 83. CHINA ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 84. CHINA ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 85. CHINA ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 86. INDIA ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 87. INDIA ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 88. INDIA ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 89. INDIA ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 90. INDIA ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 91. INDIA ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 92. INDONESIA ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 93. INDONESIA ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 94. INDONESIA ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 95. INDONESIA ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 96. INDONESIA ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 97. INDONESIA ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. JAPAN ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 99. JAPAN ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 100. JAPAN ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 101. JAPAN ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 102. JAPAN ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 103. JAPAN ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 104. MALAYSIA ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 105. MALAYSIA ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 106. MALAYSIA ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 107. MALAYSIA ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 108. MALAYSIA ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 109. MALAYSIA ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 110. PHILIPPINES ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 111. PHILIPPINES ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 112. PHILIPPINES ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 113. PHILIPPINES ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 114. PHILIPPINES ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 115. PHILIPPINES ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 116. SINGAPORE ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 117. SINGAPORE ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 118. SINGAPORE ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 119. SINGAPORE ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 120. SINGAPORE ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 121. SINGAPORE ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 122. SOUTH KOREA ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 123. SOUTH KOREA ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 124. SOUTH KOREA ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 125. SOUTH KOREA ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 126. SOUTH KOREA ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 127. SOUTH KOREA ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. TAIWAN ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 129. TAIWAN ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 130. TAIWAN ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 131. TAIWAN ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 132. TAIWAN ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 133. TAIWAN ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 134. THAILAND ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 135. THAILAND ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 136. THAILAND ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 137. THAILAND ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 138. THAILAND ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 139. THAILAND ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 140. VIETNAM ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 141. VIETNAM ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 142. VIETNAM ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 143. VIETNAM ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 144. VIETNAM ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 145. VIETNAM ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA ANTI-THROMBIN III TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 153. DENMARK ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 154. DENMARK ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 155. DENMARK ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 156. DENMARK ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 157. DENMARK ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 158. DENMARK ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 159. EGYPT ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 160. EGYPT ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 161. EGYPT ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 162. EGYPT ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 163. EGYPT ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 164. EGYPT ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 165. FINLAND ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 166. FINLAND ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 167. FINLAND ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 168. FINLAND ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 169. FINLAND ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 170. FINLAND ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. FRANCE ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 172. FRANCE ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 173. FRANCE ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 174. FRANCE ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 175. FRANCE ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 176. FRANCE ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 177. GERMANY ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 178. GERMANY ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 179. GERMANY ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 180. GERMANY ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 181. GERMANY ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 182. GERMANY ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 183. ISRAEL ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 184. ISRAEL ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 185. ISRAEL ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 186. ISRAEL ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 187. ISRAEL ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 188. ISRAEL ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. ITALY ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 190. ITALY ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 191. ITALY ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 192. ITALY ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 193. ITALY ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 194. ITALY ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 195. NETHERLANDS ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 196. NETHERLANDS ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 197. NETHERLANDS ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 198. NETHERLANDS ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 199. NETHERLANDS ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 201. NIGERIA ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 202. NIGERIA ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 203. NIGERIA ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 204. NIGERIA ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 205. NIGERIA ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 206. NIGERIA ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 207. NORWAY ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 208. NORWAY ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 209. NORWAY ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 210. NORWAY ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 211. NORWAY ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 212. NORWAY ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 213. POLAND ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 214. POLAND ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 215. POLAND ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 216. POLAND ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 217. POLAND ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 218. POLAND ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 219. QATAR ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 220. QATAR ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 221. QATAR ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 222. QATAR ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 223. QATAR ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 224. QATAR ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 225. RUSSIA ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 226. RUSSIA ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 227. RUSSIA ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 228. RUSSIA ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 229. RUSSIA ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 230. RUSSIA ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 232. SAUDI ARABIA ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 234. SAUDI ARABIA ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 236. SAUDI ARABIA ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 237. SOUTH AFRICA ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 238. SOUTH AFRICA ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 240. SOUTH AFRICA ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 242. SOUTH AFRICA ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. SPAIN ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 244. SPAIN ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 245. SPAIN ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 246. SPAIN ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 247. SPAIN ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 248. SPAIN ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 249. SWEDEN ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 250. SWEDEN ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 251. SWEDEN ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 252. SWEDEN ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 255. SWITZERLAND ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 256. SWITZERLAND ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 257. SWITZERLAND ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 261. TURKEY ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 262. TURKEY ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 263. TURKEY ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 264. TURKEY ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 265. TURKEY ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 266. TURKEY ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 267. UNITED ARAB EMIRATES ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 268. UNITED ARAB EMIRATES ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 269. UNITED ARAB EMIRATES ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 270. UNITED ARAB EMIRATES ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 271. UNITED ARAB EMIRATES ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 272. UNITED ARAB EMIRATES ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 273. UNITED KINGDOM ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 274. UNITED KINGDOM ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 275. UNITED KINGDOM ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 276. UNITED KINGDOM ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 277. UNITED KINGDOM ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 278. UNITED KINGDOM ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 279. ANTI-THROMBIN III TESTING MARKET SHARE, BY KEY PLAYER, 2023
TABLE 280. ANTI-THROMBIN III TESTING MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Anti-Thrombin III Testing Market, which are profiled in this report, include:
  • Abbott Laboratories
  • Agilent Technologies
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories
  • bioMérieux
  • Chrono-log Corporation
  • Danaher Corporation
  • DiaSorin
  • Grifols
  • Immucor
  • Instrumentation Laboratory
  • Merck KGaA
  • PerkinElmer
  • Quidel Corporation
  • Roche Diagnostics
  • Sekisui Diagnostics
  • Siemens Healthineers
  • Sysmex Corporation
  • Thermo Fisher Scientific
  • Werfen

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages197
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 99.84 Million
Forecasted Market Value ( USD ) by 2030 $ 171.37 Million
Compound Annual Growth Rate9.3%
Regions CoveredGlobal
No. of Companies Mentioned20

Related Topics

Related Reports

Anti-thrombin III Testing Market 2024-2028 - Product Image

Anti-thrombin III Testing Market 2024-2028

  • Report
  • 153 Pages
  • Global
From
Antithrombin Market by Formulation, Source, Type, Route, Application - Global Forecast 2025-2030 - Product Image

Antithrombin Market by Formulation, Source, Type, Route, Application - Global Forecast 2025-2030

  • Report
  • 188 Pages
  • Global
From
Antithrombin - Global Strategic Business Report - Product Image

Antithrombin - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
2024-2028 Global Antithrombin II Testing in 90 Countries: Five-Year Volume and Sales Forecasts, Supplier Sales and Shares, Competitive Analysis, Diagnostic Assays and Instrumentation - Product Image

2024-2028 Global Antithrombin II Testing in 90 Countries: Five-Year Volume and Sales Forecasts, Supplier Sales and Shares, Competitive Analysis, Diagnostic Assays and Instrumentation

  • Report
  • Global
From
2024 Global Coagulation Testing Market in the US, Europe, Japan - Hemostasis Analyzers and Consumables - Supplier Shares, 2023-2028 - Product Image

2024 Global Coagulation Testing Market in the US, Europe, Japan - Hemostasis Analyzers and Consumables - Supplier Shares, 2023-2028

  • Report
  • Europe, Global, Japan, ... Europe, Global, Japan, United States
From

About the Antithrombin Test Market

The Antithrombin Test is a coagulation and hemostasis test used to measure the activity of antithrombin, a protein in the blood that helps to prevent the formation of blood clots. It is used to diagnose and monitor conditions such as thrombophilia, a disorder that increases the risk of blood clots, and to assess the risk of thromboembolism, a condition in which a clot forms in a blood vessel and travels to another part of the body. The test is performed using a sample of blood, which is then analyzed in a laboratory. The Antithrombin Test market is composed of a variety of companies that provide testing services, reagents, and instruments. These companies include Siemens Healthineers, Abbott Laboratories, Roche Diagnostics, Ortho Clinical Diagnostics, Sysmex Corporation, and Grifols. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.